Form 4: Immunocore Director Ratcliffe Acquires Share Options
SEC Form 4 Filing
Director Peter John Ratcliffe acquired 14,534 share options in Immunocore Holdings plc on May 23, 2024.
Summary
- Peter John Ratcliffe, a director of Immunocore Holdings plc, acquired 14,534 share options on May 23, 2024.
- The exercise price of these options is $50.47.
- The options vest on the earlier of May 23, 2025, or the day before the next annual general meeting, contingent on continuous service.
- The options expire on May 22, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a director acquiring share options, which can be seen as a mild positive, but it's not a major event.
Positives
- A director's acquisition of share options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The acquisition of share options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of transaction: Director Ratcliffe acquired share options. |
| 05/23/2025 | Earliest vesting date for the share options, contingent on continuous service. |
| 05/22/2034 | Expiration date of the share options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.